The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...
The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.
Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...
Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...
Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...
Ustekinumab-stba is approved for multiple conditions, showing comparable efficacy and safety to Stelara in clinical trials. The biosimilar will be available in subcutaneous and intravenous forms ...
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...
Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...
Biocon added 3.69% to Rs 371.85 after the company said that Biocon Biologics has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for Ustekinumab BS subcutaneous ...
According to Celltrion, STEQEYMA is expected to be marketed in the United States beginning in February 2025. DISCLAIMER: Because of the generality of this update, the information provided herein may ...
Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...